Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study

Moyses Szklo, James R Cerhan, Ana V. Diez-Roux, Lloyd Chambless, Lawton Cooper, Aaron R. Folsom, Linda P. Fried, David S Knopman, F. Javier Nieto

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The association of estrogen replacement therapy (ERT) with cognitive functioning was assessed in 6,110 women aged 48-67 years participating in the Atherosclerosis Risk in Communities (ARIC) study, a multicenter longitudinal investigation. ERT was evaluated in relation to results of three cognitive tests (the Delayed Word Recall (DWR) Test, the Digit Symbol Subtest of the Wechsler Adult Intelligence Scale-Revised (DSS/WAIS-R), and the Word Fluency (WF) Test) using data from the first follow-up visit of the cohort (1990- 1992). No consistent associations were seen between ERT and either the DWR test or the DSS/WAIS-R after adjusting for age, education, and additional covariates previously found to be associated with cognitive function scores. Among surgically menopausal women aged 48-57 years, adjusted mean WF scores were slightly greater in ERT current users (mean WF 35.9) than in never users (mean WF 33.5) (p < 0.02); and within current users, adjusted WF scores increased with duration of ERT use. However, the finding that ERT was associated with a slightly higher level of performance on only one of three measures offers little support for the hypothesis that ERT has a major protective effect on cognitive function in women less than 68 years of age. The generalizability of these findings to older women who are more likely to experience cognitive decline and who may be using ERT for longer periods of time is limited by the relatively young age of the cohort.

Original languageEnglish (US)
Pages (from-to)1048-1057
Number of pages10
JournalAmerican Journal of Epidemiology
Volume144
Issue number11
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Estrogen Replacement Therapy
Atherosclerosis
Intelligence
Cognition
Multicenter Studies
Education

Keywords

  • cognition
  • cognition disorders
  • estrogen replacement therapy
  • menopause
  • women's health

ASJC Scopus subject areas

  • Epidemiology

Cite this

Szklo, M., Cerhan, J. R., Diez-Roux, A. V., Chambless, L., Cooper, L., Folsom, A. R., ... Nieto, F. J. (1996). Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study. American Journal of Epidemiology, 144(11), 1048-1057.

Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study. / Szklo, Moyses; Cerhan, James R; Diez-Roux, Ana V.; Chambless, Lloyd; Cooper, Lawton; Folsom, Aaron R.; Fried, Linda P.; Knopman, David S; Nieto, F. Javier.

In: American Journal of Epidemiology, Vol. 144, No. 11, 01.12.1996, p. 1048-1057.

Research output: Contribution to journalArticle

Szklo, M, Cerhan, JR, Diez-Roux, AV, Chambless, L, Cooper, L, Folsom, AR, Fried, LP, Knopman, DS & Nieto, FJ 1996, 'Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study', American Journal of Epidemiology, vol. 144, no. 11, pp. 1048-1057.
Szklo, Moyses ; Cerhan, James R ; Diez-Roux, Ana V. ; Chambless, Lloyd ; Cooper, Lawton ; Folsom, Aaron R. ; Fried, Linda P. ; Knopman, David S ; Nieto, F. Javier. / Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study. In: American Journal of Epidemiology. 1996 ; Vol. 144, No. 11. pp. 1048-1057.
@article{b776125844504a7baff8d1ee5d65e098,
title = "Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study",
abstract = "The association of estrogen replacement therapy (ERT) with cognitive functioning was assessed in 6,110 women aged 48-67 years participating in the Atherosclerosis Risk in Communities (ARIC) study, a multicenter longitudinal investigation. ERT was evaluated in relation to results of three cognitive tests (the Delayed Word Recall (DWR) Test, the Digit Symbol Subtest of the Wechsler Adult Intelligence Scale-Revised (DSS/WAIS-R), and the Word Fluency (WF) Test) using data from the first follow-up visit of the cohort (1990- 1992). No consistent associations were seen between ERT and either the DWR test or the DSS/WAIS-R after adjusting for age, education, and additional covariates previously found to be associated with cognitive function scores. Among surgically menopausal women aged 48-57 years, adjusted mean WF scores were slightly greater in ERT current users (mean WF 35.9) than in never users (mean WF 33.5) (p < 0.02); and within current users, adjusted WF scores increased with duration of ERT use. However, the finding that ERT was associated with a slightly higher level of performance on only one of three measures offers little support for the hypothesis that ERT has a major protective effect on cognitive function in women less than 68 years of age. The generalizability of these findings to older women who are more likely to experience cognitive decline and who may be using ERT for longer periods of time is limited by the relatively young age of the cohort.",
keywords = "cognition, cognition disorders, estrogen replacement therapy, menopause, women's health",
author = "Moyses Szklo and Cerhan, {James R} and Diez-Roux, {Ana V.} and Lloyd Chambless and Lawton Cooper and Folsom, {Aaron R.} and Fried, {Linda P.} and Knopman, {David S} and Nieto, {F. Javier}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "144",
pages = "1048--1057",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study

AU - Szklo, Moyses

AU - Cerhan, James R

AU - Diez-Roux, Ana V.

AU - Chambless, Lloyd

AU - Cooper, Lawton

AU - Folsom, Aaron R.

AU - Fried, Linda P.

AU - Knopman, David S

AU - Nieto, F. Javier

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The association of estrogen replacement therapy (ERT) with cognitive functioning was assessed in 6,110 women aged 48-67 years participating in the Atherosclerosis Risk in Communities (ARIC) study, a multicenter longitudinal investigation. ERT was evaluated in relation to results of three cognitive tests (the Delayed Word Recall (DWR) Test, the Digit Symbol Subtest of the Wechsler Adult Intelligence Scale-Revised (DSS/WAIS-R), and the Word Fluency (WF) Test) using data from the first follow-up visit of the cohort (1990- 1992). No consistent associations were seen between ERT and either the DWR test or the DSS/WAIS-R after adjusting for age, education, and additional covariates previously found to be associated with cognitive function scores. Among surgically menopausal women aged 48-57 years, adjusted mean WF scores were slightly greater in ERT current users (mean WF 35.9) than in never users (mean WF 33.5) (p < 0.02); and within current users, adjusted WF scores increased with duration of ERT use. However, the finding that ERT was associated with a slightly higher level of performance on only one of three measures offers little support for the hypothesis that ERT has a major protective effect on cognitive function in women less than 68 years of age. The generalizability of these findings to older women who are more likely to experience cognitive decline and who may be using ERT for longer periods of time is limited by the relatively young age of the cohort.

AB - The association of estrogen replacement therapy (ERT) with cognitive functioning was assessed in 6,110 women aged 48-67 years participating in the Atherosclerosis Risk in Communities (ARIC) study, a multicenter longitudinal investigation. ERT was evaluated in relation to results of three cognitive tests (the Delayed Word Recall (DWR) Test, the Digit Symbol Subtest of the Wechsler Adult Intelligence Scale-Revised (DSS/WAIS-R), and the Word Fluency (WF) Test) using data from the first follow-up visit of the cohort (1990- 1992). No consistent associations were seen between ERT and either the DWR test or the DSS/WAIS-R after adjusting for age, education, and additional covariates previously found to be associated with cognitive function scores. Among surgically menopausal women aged 48-57 years, adjusted mean WF scores were slightly greater in ERT current users (mean WF 35.9) than in never users (mean WF 33.5) (p < 0.02); and within current users, adjusted WF scores increased with duration of ERT use. However, the finding that ERT was associated with a slightly higher level of performance on only one of three measures offers little support for the hypothesis that ERT has a major protective effect on cognitive function in women less than 68 years of age. The generalizability of these findings to older women who are more likely to experience cognitive decline and who may be using ERT for longer periods of time is limited by the relatively young age of the cohort.

KW - cognition

KW - cognition disorders

KW - estrogen replacement therapy

KW - menopause

KW - women's health

UR - http://www.scopus.com/inward/record.url?scp=0029806643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029806643&partnerID=8YFLogxK

M3 - Article

C2 - 8942436

AN - SCOPUS:0029806643

VL - 144

SP - 1048

EP - 1057

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 11

ER -